Opyl (ASX:OPL) is a new generation company working at the intersection of artificial intelligence, social media and clinical trials.
The next stage of the company's AI platform will involve increasing the data pool from additional clinical data sources and expanding the variables in order to further train the algorithm and refine the specificity and reliability.